ECS Botanics (ASX:ECS) - Managing Director and Founder, Alexander Keach
Managing Director and Founder, Alexander Keach
Source: ECS Botanics
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ECS Botanics (ECS) is poised for a strong year as increasing demand props up its sales figures
  • Its facility in Victoria has recorded sales for the current quarter of around $543,000
  • Total sales for the 2021 calendar year are now expected to hit $2 million thanks largely to new customer contracts
  • To meet the demand, ECS is building another 2000 square metres of protective cropping enclosures, adding to the current 1000 square metres
  • Shares in ECS Botanics are trading up 9.76 per cent at 4.5 cents each at 10:57 am AEST

Medical cannabis grower ECS Botanics (ECS) is poised for a strong year as increasing demand props up its sales figures.

Its facility in Victoria — which produces premium dried flower, biomass and oils – recently completed its first commercial harvest and has recorded sales for the current quarter of around $543,000.

Total sales for the 2021 calendar year were now expected to hit $2 million thanks largely to new customer contracts, the company said.

To meet the growing demand ECS is in the process of expanding its Victorian operations by building another 2000 square metres of protective cropping enclosures, significantly expanding on the current 1000 square metres.

In a statement released this morning, ECS said the increased capacity also afforded the flexibility to support its customer base by cultivating specific strains under contract.

ECS is one of only a few companies that hold several Office of Drug Control and TGA Manufacturing licences, but said it would need to extend its Good Manufacturing Practice (GMP) licence if it’s to successfully meet the existing levels of demand.

To that end, its processing facility has been upgraded to include pharmaceutical-grade cleanrooms for packaging dried flower.

“Based on the orders received and the increased enquiries from local and European customers, we are increasing our premium dried flower cultivation capacity threefold,” Managing Director Alex Keach said.

“There is significant momentum in the business and several developments are imminent.”

Shares in ECS Botanics were trading up 9.76 per cent at 4.5 cents each at 10:57 am AEST.

ECS by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Botanix isn’t sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription…

Singular Health launches upgraded DICOM viewer, with patient-friendly features for engagement with medical records

Singular Health Ltd has launched an upgraded version of its DICOM viewer, set to allow greater…